AR033555A1 - Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos - Google Patents

Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos

Info

Publication number
AR033555A1
AR033555A1 ARP010103839A ARP010103839A AR033555A1 AR 033555 A1 AR033555 A1 AR 033555A1 AR P010103839 A ARP010103839 A AR P010103839A AR P010103839 A ARP010103839 A AR P010103839A AR 033555 A1 AR033555 A1 AR 033555A1
Authority
AR
Argentina
Prior art keywords
product
treatment
positive
strogen
carcinoma
Prior art date
Application number
ARP010103839A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22840171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR033555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR033555A1 publication Critical patent/AR033555A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

Un producto que comprende una cantidad efectiva de una rapamicina y/o un antiestrogeno para la administracion en forma de preparacion combinada de una rapamicina y un antiestrogeno para el uso simultáneo, independiente o consecutivo en el tratamiento o inhibicion del carcinoma de receptor de estrogeno positivo y uso de dicho producto para preparar medicamentos.
ARP010103839A 2000-08-11 2001-08-10 Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos AR033555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22432600P 2000-08-11 2000-08-11

Publications (1)

Publication Number Publication Date
AR033555A1 true AR033555A1 (es) 2003-12-26

Family

ID=22840171

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103839A AR033555A1 (es) 2000-08-11 2001-08-10 Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos

Country Status (15)

Country Link
US (1) US6511986B2 (es)
EP (1) EP1318837B1 (es)
JP (1) JP2004507465A (es)
CN (1) CN100448487C (es)
AR (1) AR033555A1 (es)
AT (1) ATE278421T1 (es)
AU (1) AU2001283139A1 (es)
CA (1) CA2416976C (es)
DE (1) DE60106281T2 (es)
DK (1) DK1318837T3 (es)
ES (1) ES2228932T3 (es)
HK (1) HK1056687A1 (es)
MX (1) MXPA03001245A (es)
PT (1) PT1318837E (es)
WO (1) WO2002013802A2 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US8512960B2 (en) * 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US6720159B1 (en) 1997-12-16 2004-04-13 A&G Pharmaceutical, Inc. 88KDA tumorigenic growth factor and antagonists
US7617145B1 (en) * 2000-10-24 2009-11-10 Worldwide Farm Equipment Auctions.Com Ltd. Adaptive bidding increments in an online auction system
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
AU2011226833B9 (en) * 2001-02-19 2014-07-03 Novartis Ag Cancer treatment
AU2016206379B2 (en) * 2001-02-19 2017-09-14 Novartis Ag Cancer Treatment
RU2322981C2 (ru) 2001-02-19 2008-04-27 Новартис Аг Комбинация и способ предупреждения рака молочной железы
DE60231868D1 (de) 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
WO2003005954A2 (en) * 2001-07-09 2003-01-23 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
AU2003243226A1 (en) * 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
AU2003297217B2 (en) * 2003-02-26 2010-01-07 A & G Pharmaceuticals, Inc. Methods for increasing the proliferation of B cells
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
JP2007524622A (ja) * 2003-06-23 2007-08-30 エイアンドジー ファーマスーティカルズ インコーポレイテッド 抗癌治療に対する腫瘍細胞の感受性を回復させてアポトーシスを誘導するための組成物及び方法
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
EP1660010B1 (en) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
AU2005302004A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mTOR inhibitor in treatment of uterine leiomyoma
CN113952338A (zh) * 2005-02-03 2022-01-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0608885A2 (pt) 2005-03-07 2017-02-21 Wyeth Corp composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
EP1865938A4 (en) * 2005-03-22 2008-09-24 Repros Therapeutics Inc DOSAGE SCHEMES FOR TRANS-CLOMIPHENE
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
RU2470668C2 (ru) * 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (en) * 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
CN102940619A (zh) 2007-10-16 2013-02-27 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
ES2835349T3 (es) 2008-06-17 2021-06-22 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105963313A (zh) 2008-08-04 2016-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimens containing neratinib for the treatment of cancer
JP2013528223A (ja) 2010-06-10 2013-07-08 アラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその用途
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
EA029559B1 (ru) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
WO2014070523A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
RU2560708C1 (ru) * 2014-03-24 2015-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической и экспериментальной лимфологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКЭЛ" СО РАМН) Способ воздействия на клетки гепатокарциномы в зависимости от стадии их дифференцировки нанопрепаратами лития
HUE055321T2 (hu) 2015-10-01 2021-11-29 Olema Pharmaceuticals Inc Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok
JP6920709B2 (ja) 2015-12-09 2021-08-18 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ ベンゾチオフェン系選択的エストロゲン受容体ダウンレギュレーター
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
JP2019520379A (ja) 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
KR102462433B1 (ko) 2016-10-11 2022-11-03 듀크 유니버시티 Er+ 유방암의 라소폭시펜 치료
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
WO2018129387A1 (en) 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
CA3052810A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CN110913861B (zh) 2017-06-29 2024-01-09 G1治疗公司 G1t38的形态学形式及其制造方法
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
CA2416976A1 (en) 2002-02-21
DE60106281D1 (de) 2004-11-11
HK1056687A1 (en) 2004-02-27
DE60106281T2 (de) 2005-02-24
AU2001283139A1 (en) 2002-02-25
MXPA03001245A (es) 2003-05-27
JP2004507465A (ja) 2004-03-11
ATE278421T1 (de) 2004-10-15
WO2002013802A3 (en) 2003-03-27
DK1318837T3 (da) 2005-01-10
ES2228932T3 (es) 2005-04-16
EP1318837B1 (en) 2004-10-06
US20020045638A1 (en) 2002-04-18
CN1446106A (zh) 2003-10-01
WO2002013802A2 (en) 2002-02-21
CN100448487C (zh) 2009-01-07
CA2416976C (en) 2008-05-20
EP1318837A2 (en) 2003-06-18
PT1318837E (pt) 2004-12-31
US6511986B2 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
CO6160297A2 (es) Uso de valerato de estradiol o 17beta-estradiol en combinacion de dienogest en una terapia oral para mantener y/o incrementar la libido femenina
PT954314E (pt) Formas de dosagem farmaceutica para melhorar a disfuncao erectil masculina
AU2682401A (en) Flavonoid drug and dosage form, its production and use
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
AR032132A1 (es) Composicion farmaceutica que comprende una combinacion de un compuesto de tramadol y una droga anticonvulsiva y uso de la combinacion para preparar un medicamento
BR0107535A (pt) Uso de carotenóides e forma de dosagem unitária destes
UY27720A1 (es) Aroilpiridinonas monocíclicas,
HK1053118A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof.
ES2172533T3 (es) Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida.
CZ20023753A3 (cs) Substituované thioacetamidy, jejich použití pro výrobu léčiva a farmaceutický prostředek s jejich obsahem
MXPA03005731A (es) Articulo absorbente que tiene tratamientos medicinales liberables.
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
AR025330A1 (es) Combinacion de sustancias activas con clonidina
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
AR028023A1 (es) Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos
DE50105771D1 (de) Ibuprofen-wirkstoffzubereitung
UY27458A1 (es) Tetrahidroquinolinas
PT1150704E (pt) Melagatran para o tratamento da inflamacao
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AR029451A1 (es) Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia

Legal Events

Date Code Title Description
FB Suspension of granting procedure